{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:28:42Z","timestamp":1791293322932,"version":"4.1.0"},"reference-count":39,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2004,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The development of resistance to sulfadoxine-pyrimethamine by\n            <jats:italic>Plasmodium<\/jats:italic>\n            parasites is a major problem for the effective treatment of malaria, especially\n            <jats:italic>P. falciparum<\/jats:italic>\n            malaria. Although the molecular basis for parasite resistance is known, the factors promoting the development and transmission of these resistant parasites are less clear. This paper reports the results of a quantitative comparison of factors previously hypothesized as important for the development of drug resistance, drug dosage, time of treatment, and drug elimination half-life, with an in-host dynamics model of\n            <jats:italic>P. falciparum<\/jats:italic>\n            malaria in a malaria-nai\u0308ve host. The results indicate that the development of drug resistance can be categorized into three stages. The first is the selection of existing parasites with genetic mutations in the dihydrofolate reductase or dihydropteroate synthetase gene. This selection is driven by the long half-life of the sulfadoxine-pyrimethamine combination. The second stage involves the selection of parasites with allelic types of higher resistance within the host during an infection. The timing of treatment relative to initiation of a specific anti-\n            <jats:italic>P. falciparum<\/jats:italic>\n            EMP1 immune response is an important factor during this stage, as is the treatment dosage. During the third stage, clinical treatment failure becomes prevalent as the parasites develop sufficient resistance mutations to survive therapeutic doses of the drug combination. Therefore, the model output reaffirms the importance of correct treatment of confirmed malaria cases in slowing the development of parasite resistance to sulfadoxine-pyrimethamine.\n          <\/jats:p>","DOI":"10.1128\/aac.48.6.2116-2123.2004","type":"journal-article","created":{"date-parts":[[2004,5,21]],"date-time":"2004-05-21T18:38:42Z","timestamp":1085164722000},"page":"2116-2123","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":77,"title":["Evolution of Resistance to Sulfadoxine-Pyrimethamine in\n            <i>Plasmodium falciparum<\/i>"],"prefix":"10.1128","volume":"48","author":[{"given":"Michelle L.","family":"Gatton","sequence":"first","affiliation":[{"name":"Malaria and Scabies Group, Queensland Institute of Medical Research, Royal Brisbane Hospital, Brisbane, Queensland 4029"},{"name":"Australian Centre for International and Tropical Health and Nutrition, University of Queensland, Queensland 4072"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura B","family":"Martin","sequence":"additional","affiliation":[{"name":"Malaria and Scabies Group, Queensland Institute of Medical Research, Royal Brisbane Hospital, Brisbane, Queensland 4029"},{"name":"Australian Centre for International and Tropical Health and Nutrition, University of Queensland, Queensland 4072"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Drug Resistance and Diagnostics, Australian Army Malaria Institute, Gallipoli Barracks, Enoggera, Queensland 4051, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg294"},{"key":"e_1_3_3_3_2","first-page":"90","volume":"90","year":"1997","unstructured":"Basco, L. K., and J. Le-Bras. 1997. In vitro sensitivity of Plasmodium falciparum to anti-folinic agents (trimethoprim, pyrimethamine, cycloguanil): a study of 29 African strains. Bull. Soc. Pathol. Exot.90:90-93.","journal-title":"Bull. Soc. Pathol. Exot."},{"key":"e_1_3_3_4_2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.4269\/ajtmh.2000.62.271","volume":"62","year":"2000","unstructured":"Basco, L. K., and P. Ringwald. 2000. Molecular epidemiology of malaria in Yaounde, Cameroon. VI. Sequence variations in the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene and in vitro resistance to pyrimethamine and cycloguanil. Am. J. Trop. Med. Hyg.62:271-276.","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/315731"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.7.1811"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.23.9109"},{"key":"e_1_3_3_8_2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0035-9203(02)90254-3","volume":"96","year":"2002","unstructured":"Eskandarian, A., H. Keshavarz, L. K. Basco, and F. Mahboudi. 2002. Do mutations in Plasmodium falciparum dihydropteroate synthase and dihyrofolate reductase confer resistance to sulfadoxine-pyrimethamine in Iran? Trans. R. Soc. Trop. Med. Hyg.96:96-98.","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"e_1_3_3_9_2","doi-asserted-by":"crossref","first-page":"467","DOI":"10.4269\/ajtmh.2002.66.467","volume":"66","year":"2002","unstructured":"Gatton, M. L., and Q. Cheng. 2002. Evaluation of the pyrogenic threshold for Plasmodium falciparum malaria in naive individuals. Am. J. Trop. Med. Hyg.66:467-473.","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"e_1_3_3_10_2","doi-asserted-by":"crossref","unstructured":"Gatton M. L. and Q. Cheng. 2004. Investigating antigenic variation and other parasite-host interactions in Plasmodium falciparum infection in na\u00efve hosts. Parasitology 128 : 367-376.","DOI":"10.1017\/S0031182003004608"},{"key":"e_1_3_3_11_2","first-page":"537","volume":"123","year":"2001","unstructured":"Gatton, M. L., W. Hogarth, and A. Saul. 2001. Time of treatment influences the appearance of drug-resistant parasites in Plasmodium falciparum infections. Parasitology123:537-546.","journal-title":"Parasitology"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-4758(00)01707-5"},{"key":"e_1_3_3_13_2","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1098\/rstb.2001.1036","volume":"357","year":"2002","unstructured":"Hastings, I. M., W. M. Watkins, and N. J. White. 2002. The evolution of drug-resistant malaria: the role of drug elimination half-life. Phil. Trans. R. Soc. London B Biol. Sci.357:505-519.","journal-title":"Phil. Trans. R. Soc. London B Biol. Sci."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4922(01)02085-2"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06201-8"},{"key":"e_1_3_3_16_2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4269\/ajtmh.1999.61.463","volume":"61","year":"1999","unstructured":"Jelinek, T., A. H. Kilian, G. Kabagambe, and F. Von-Sonnenburg. 1999. Plasmodium falciparum resistance to sulfadoxine\/pyrimethamine in Uganda: correlation with polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes. Am. J. Trop. Med. Hyg.61:463-466.","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"e_1_3_3_17_2","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1046\/j.1365-3156.1998.00280.x","volume":"3","year":"1998","unstructured":"Jelinek, T., A. M. R\u00f8nn, M. M. Lemnge, J. Curtis, J. Mhina, M. T. Duraisingh, I. C. Bygbjerg, and D. C. Warhurst. 1998. Polymorphisms in the dihydrofolate reductase (DHFR) and dihydropteroate synthetase (DHPS) genes of Plasmodium falciparum and in vivo resistance to sulphadoxine\/pyrimethamine in isolates from Tanzania. Trop. Med. Int. Health3:605-609.","journal-title":"Trop. Med. Int. Health"},{"key":"e_1_3_3_18_2","unstructured":"Martindale W. 1993. The extra pharmacopoeia 30th ed. p. 205 406. Pharmaceutical Press London England."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2000.62.396"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06344-9"},{"key":"e_1_3_3_21_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0035-9203(01)90329-3","volume":"95","year":"2001","unstructured":"Nagesha, H. S., Din-Syafruddin, G. J. Casey, A. I. Susanti, D. J. Fryauff, J. C. Reeder, and A. F. Cowman. 2001. Mutations in the pfmdr1, dhfr and dhps genes of Plasmodium falciparum are associated with in-vivo drug resistance in West Papua, Indonesia. Trans. R. Soc. Trop. Med. Hyg.95:43-49.","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/molbev\/msg162"},{"key":"e_1_3_3_23_2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0035-9203(01)90332-3","volume":"95","year":"2001","unstructured":"Ndounga, M., L. K. Basco, and P. Ringwald. 2001. Evaluation of a new sulfadoxine sensitivity assay in vitro for field isolates of Plasmodium falciparum. Trans. R. Soc. Trop. Med. Hyg.95:55-57.","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"e_1_3_3_24_2","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1086\/315520","volume":"181","year":"2000","unstructured":"Nzila, A. M., E. Nduati, E. K. Mberu, C. Hopkins Sibley, S. A. Monks, P. A. Winstanley, and W. M. Watkins. 2000. Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate pyrimethamine\/sulfadoxine compared with the shorter-acting chlorproguanil\/dapson on Kenyan Plasmodium falciparum. J. Infect. Dis.181:2023-2028.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_3_25_2","unstructured":"Paget-McNicol S. 2002. Estimation of mutation and switching rates in Plasmodium falciparum genes. Ph.D. thesis. University of Queensland Queensland Australia."},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0031182001007739"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.8.3018"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12951-0"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.12.3414-3424.2000"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1086\/367705"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.25.13944"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0074-02762000000500020"},{"key":"e_1_3_3_33_2","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1046\/j.1365-2958.1999.01437.x","volume":"32","year":"1999","unstructured":"Wang, P., R. K. Brobey, T. Horii, P. F. Sims, and J. E. Hyde. 1999. Utilization of exogenous folate in the human malaria parasite Plasmodium falciparum and its critical role in antifolate drug synergy. Mol. Microbiol.32:1254-1262.","journal-title":"Mol. Microbiol."},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-6851(97)00114-X"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.1997.2821646.x"},{"key":"e_1_3_3_36_2","first-page":"115","volume":"60","year":"1982","unstructured":"Weidekamm, E., H. Plozza-Nottebrock, I. Forgo, and U. C. Dubach. 1982. Plasma concentrations of pyrimethamine and sulfadoxine and evaluation of pharmacokinetic data by computerized curve fitting. Bull. W.H.O.60:115-122.","journal-title":"Bull. W.H.O."},{"key":"e_1_3_3_37_2","first-page":"739","volume":"354","year":"1999","unstructured":"White, N. 1999. Antimalarial drug resistance and combination chemotherapy. Phil. Trans. R Soc. London B Biol. Sci.354:739-749.","journal-title":"Sci."},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.7.1413"},{"key":"e_1_3_3_39_2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1098\/rspb.2002.2241","volume":"270","year":"2003","unstructured":"White, N. J., and W. Pongtavornpinyo. 2003. The de novo selection of drug-resistant malaria parasites. Proc. R Soc. London B Biol. Sci.270:545-554.","journal-title":"Proc. R Soc. London B Biol. Sci."},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.4.948"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.48.6.2116-2123.2004","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.48.6.2116-2123.2004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:23:45Z","timestamp":1645467825000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.48.6.2116-2123.2004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["10.1128\/AAC.48.6.2116-2123.2004"],"URL":"https:\/\/doi.org\/10.1128\/aac.48.6.2116-2123.2004","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6]]},"assertion":[{"value":"2003-10-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-02-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-06-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}